Robust, randomised, placebo-controlled human trials are essentially absent for both peptides
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters
Minimal Side Effects & High Safety Profile Compared to many pharmaceuticals, peptide therapy has virtually no known side effects
Ill go into each of these treatments in more detail in future articles and videos, but heres a quick summary
Relative contraindications requiring caution include active or suspected cancer (GHK-Cu promotes angiogenesis with concern about theoretically feeding tumors, though conflicting data shows documented anti-cancer gene expression effects requiring medical supervision), severe organ dysfunction (kidney or liver failure may slow peptide clearance), hemochromatosis or copper overload conditions, autoimmune disorders, and patients on immunosuppressants or blood thinners